Neurogene Operating Cycle from 2010 to 2026
| NGNE Stock | 18.31 0.68 3.58% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 230.13 | Current Value 241.63 | Quarterly Volatility 108.76497978 |
Check Neurogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Other Operating Expenses of 100.9 M or Research Development of 73.6 M, as well as many indicators such as Price To Sales Ratio of 410, Dividend Yield of 0.0 or PTB Ratio of 1.41. Neurogene financial statements analysis is a perfect complement when working with Neurogene Valuation or Volatility modules.
Neurogene | Operating Cycle | Build AI portfolio with Neurogene Stock |
Latest Neurogene's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Neurogene over the last few years. It is Neurogene's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurogene's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Neurogene Operating Cycle Regression Statistics
| Arithmetic Mean | 84.54 | |
| Geometric Mean | 36.63 | |
| Coefficient Of Variation | 128.66 | |
| Mean Deviation | 96.02 | |
| Median | 16.52 | |
| Standard Deviation | 108.76 | |
| Sample Variance | 11,830 | |
| Range | 239 | |
| R-Value | 0.78 | |
| Mean Square Error | 4,876 | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 16.87 | |
| Total Sum of Squares | 189,277 |
Neurogene Operating Cycle History
About Neurogene Financial Statements
Neurogene stakeholders use historical fundamental indicators, such as Neurogene's Operating Cycle, to determine how well the company is positioned to perform in the future. Although Neurogene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neurogene's assets and liabilities are reflected in the revenues and expenses on Neurogene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neurogene. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 230.13 | 241.63 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out the analysis of Neurogene Correlation against competitors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.